Khairulorama- Life and work notes

Pain is the predecessor of success.

MRCP notes

leave a comment »

Mrcp Part 2 Witten Exam from DR AHMED SAYEED
NEJM Medical Image Challenge from DR AHMED SAYEED
In regards to Parkinsonism,
Currently accepted practice in the management of patients with Parkinson’s disease (PD) is to delay treatment until the onset of disabling symptoms and then to introduce a dopamine receptor agonist. If the patient is elderly, levodopa is sometimes used as an initial treatment.Dopamine receptor agonists

  • e.g. Bromocriptine, ropinirole, cabergoline, apomorphine
  • ergot-derived dopamine receptor agonists (bromocriptine, cabergoline, pergolide*) have been associated with pulmonary, retroperitoneal and cardiac fibrosis. The Committee on Safety of Medicines advice that an echocardiogram, ESR, creatinine and chest x-ray should be obtained prior to treatment and patients should be closely monitored
  • patients should be warned about the potential for dopamine receptor agonists to cause impulse control disorders and excessive daytime somnolence
  • nasal congestion and postural hypotension are also seen in some patients

Levodopa

  • usually combined with a decarboxylase inhibitor (e.g. Carbidopa or benserazide) to prevent peripheral metabolism of levodopa to dopamine
  • reduced effectiveness with time (usually by 2 years)
  • unwanted effects: dyskinesia (involuntary writhing movements), ‘on-off’ effect, dry mouth, anorexia, palpitations, postural hypotension, psychosis
  • no use in neuroleptic induced parkinsonism

MAO-B (Monoamine Oxidase-B) inhibitors

  • e.g. Selegiline
  • inhibits the breakdown of dopamine secreted by the dopaminergic neurons

Amantadine

  • mechanism is not fully understood, probably increases dopamine release and inhibits its uptake at dopaminergic synapses

COMT (Catechol-O-Methyl Transferase) inhibitors

  • e.g. Entacapone
  • COMT is an enzyme involved in the breakdown of dopamine, and hence may be used as an adjunct to levodopa therapy
  • used in established PD

Antimuscarinics

  • block cholinergic receptors
  • now used more to treat drug-induced parkinsonism rather than idiopathic Parkinson’s disease
  • help tremor and rigidity
  • e.g. Procyclidine, benzotropine, trihexyphenidyl (benzhexol)

*pergolide was withdrawn from the US market in March 2007 due to concern regarding increased incidence of valvular dysfunction

Written by khairulorama

February 2, 2013 at 8:18 pm

Posted in Uncategorized

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: